文献速递产科母胎医学

先天性心脏缺陷且无创产前筛查正常时染色体微阵列的检出率

The yield of chromosomal microarray in pregnancies with congenital cardiac defects and normal noninvasive prenatal screening.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-27

基于2013-2019年全国数据库,分析1728例先天性心脏缺陷胎儿在无创产前筛查正常后行染色体微阵列分析的结果,发现临床显著异常检出率为5.4%,残留风险在孤立性缺陷为2.0%-2.8%、非孤立性为4.5%-5.9%,均高于低风险对照人群。

要点

  • 先心病胎儿无创筛查正常后,染色体微阵列仍可检出5.4%的临床显著异常。
  • 孤立性先心病残留风险2.0%-2.8%,非孤立性4.5%-5.9%,均高于对照。
  • 室间隔缺损和右锁骨下动脉迷走等亚型的残留风险未显著高于对照。

核心结论

  • 先心病胎儿在无创产前筛查正常后,染色体微阵列检出临床显著异常的风险仍高于超声正常妊娠,应纳入诊断检测决策考量。

研究设计与样本

  • 基于全国计算机数据库的回顾性队列研究,纳入2013-2019年因先心病行染色体微阵列分析的1728例胎儿,并与本地低风险妊娠队列比较。

主要发现

  • 1728例先心病胎儿中93例(5.4%)检出临床显著染色体微阵列结果,相对风险2.7(95%CI 2.3-3.1)。
  • 15例(16.1%)发现独有变异。
  • 孤立性先心病中无创产前筛查检出率从1.0%(针对3种常见三体)到2.2%(针对5种常见非整倍体及22q11.2缺失)。
  • 非孤立性先心病中无创产前筛查检出率从7.8%(常见常染色体三体)到9.2%(全基因组无创产前筛查)。

关键数值与推荐

  • 无创产前筛查正常后染色体微阵列临床显著结果的残留风险:孤立性先心病2.0%-2.8%,非孤立性4.5%-5.9%。
  • 针对13、18、21、X、Y染色体的无创产前筛查后,多数先心病亚型的残留风险显著高于对照,但室间隔缺损和右锁骨下动脉迷走除外。

临床怎么用

  • 对先心病胎儿即使无创产前筛查正常,尤其非孤立性病例,应告知残留风险并讨论是否行染色体微阵列诊断检测。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence comparing the yield of chromosomal microarray analysis to noninvasive prenatal screening in pregnancies with congenital heart anomalies is currently limited. OBJECTIVE: This study aimed to examine the residual risk of clinically significant chromosomal microarray analysis results in fetuses with congenital heart defects by its various subtypes following a normal noninvasive prenatal screening. STUDY DESIGN: Using a population-based, countrywide computerized database, we retrieved the reports of all pregnancies undergoing chromosomal microarray analysis because of congenital heart defects through the years 2013-2019. We examined the risk of clinically significant (pathogenic and likely pathogenic) chromosomal microarray analysis results and compared it with the results of a local cohort of low-risk pregnancies. Of 5541 fetuses, 78 (1.4%) showed abnormal results. The residual risk of abnormal chromosomal microarray analysis results was calculated using several options-trisomies 21, 18, and 13; sex chromosome aneuploidies; 22q11.2 deletion, and deletions and duplications of at least 10 MB in size (genome-wide noninvasive prenatal screening)-following the exclusion of theoretically detectable noninvasive prenatal screening anomalies. RESULTS: Of the 1728 fetuses with congenital heart defects, 93 (5.4%) showed clinically significant chromosomal microarray analysis results (relative risk, 2.7; 95% confidence interval, 2.3-3.1). The result of pregnancies with fetuses with congenital heart defects was compared with the results of the control population. Unique variants were found in 15 pregnancies (16.1%). The detection rate of noninvasive prenatal screening in isolated congenital heart defects varied from 1.0% (aimed at 3 common trisomies) to 2.2% (aimed at 5 common aneuploidies and 22q11.2 deletion) using noninvasive prenatal screening. In nonisolated congenital heart defects, the noninvasive prenatal screening detection rates ranged from 7.8% (aimed at common autosomal trisomies) to 9.2% using genome-wide noninvasive prenatal screening. The residual risk of clinically significant chromosomal microarray analysis results following normal noninvasive prenatal screening ranged from 2.0% to 2.8% in isolated congenital heart defects and 4.5% to 5.9% in nonisolated cases and was significantly higher than those of the control cohort in all noninvasive prenatal screening options. In addition, the residual risk following noninvasive prenatal screening aimed at chromosomes 13, 18, 21, X, and Y was significantly higher than those of the control cohort for most specific congenital heart defect subtypes, except for ventricular septal defects and aberrant right subclavian artery. CONCLUSION: The residual risk of clinically significant chromosomal microarray analysis results in pregnancies with fetuses with congenital heart defects following normal noninvasive prenatal screening was higher than those in pregnancies with normal ultrasound in most isolated and nonisolated congenital heart defect subtypes. This information should be taken into account by obstetricians and genetic counselors when considering the option of diagnostic testing.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sagi-Dain L, Singer A, Segel R, et al. The yield of chromosomal microarray in pregnancies with congenital cardiac defects and normal noninvasive prenatal screening. Am J Obstet Gynecol. 2021. PMID: 34052193. doi:10.1016/j.ajog.2021.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。